Serum soluble interleukin‐2 receptor levels in hairy cell leukaemia as a marker of tumour burden with prognostic value and as a tool for disease monitoring
British Journal of Haematology · 2025
DOI: 10.1111/bjh.70059 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2025. Verfasst von Francesco Angotzi und 14 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Unit, Department of Medicine, University of Padova, Padova, Italy. Hauptthemen laut MEDLINE: Leukemia, Hairy Cell, Receptors, Interleukin-2, Biomarkers, Tumor. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Associazione Italiana per la Ricerca sul Cancro, Progetti di Rilevanza Nazionale (PRIN-PNRR), Fondazione AIRC per la ricerca sul cancro ETS.
Abstract (Originalsprache)
Leukaemic cells from hairy cell leukaemia (HCL) secrete a soluble form of the interleukin‐2 receptor (sIL‐2R) which is measurable in serum. Previous evidence suggested that sIL‐2R may correlate well with tumour burden and demonstrated a reduction in sIL‐2R levels after therapy with recombinant interferon‐α2. We evaluated the role of sIL‐2R as a new prognostic factor and as a tool for disease monitoring. sIL‐2R correlated well with other markers of neoplastic bulk and markedly decreased after treatment, with lower levels achieved in patients reaching complete remission ( p = 0.002) or negative minimal residual disease (MRD, p = 0.034). Post‐treatment levels ≤827 kU/L were strongly predictive of longer time to next treatment (TTNT) (median NR vs. 4.87 years; hazard ratio [HR]: 0.10; 95% confidence interval [CI]: 0.02–0.24; p < 0.001) and higher 5‐ and 10‐year TTNT rates (5‐year: 93% vs. 45%; 10‐year: 83% vs. 11%). Furthermore, a ≥50% increase in sIL‐2R levels over any 1‐year interval during follow‐up predicted impending relapse. In a context where patients with HCL are expected to achieve a life expectancy comparable to that of the general population, sIL‐2R has the potential to serve as a non‐invasive tool alongside MRD to predict relapse and to identify those patients who may fail to derive the most benefit from current treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hematology Unit, Department of Medicine, University of Padova, Padova, Italy.
- Immunology and Molecular Oncology Unit, Veneto Institute of Oncology (IOV-IRCCS), Padova, Italy.
- Department of Medicine, Surgical Pathology and Cytopathology Unit, University of Padova, Padua, Italy.
- Department of Integrated Diagnostic Medicine, Laboratory Medicine Unit, University of Padova, Padova, Italy.
ORCID-Profile: Francesco Angotzi, Federica Frezzato, Livio Trentin, Andrea Visentin
Förderung
- Associazione Italiana per la Ricerca sul Cancro
- Progetti di Rilevanza Nazionale (PRIN-PNRR)
- Fondazione AIRC per la ricerca sul cancro ETS
Zitieren
APA
Angotzi, F., Cellini, A., Danesin, N., Zoletto, S., Serafin, A., Cavarretta, C. A., Bevilacqua, A., Forlani, L., Tonini, A., Frezzato, F., Bonaldi, L., Pizzi, M., Faggian, D., Trentin, L., & Visentin, A. (2025). Serum soluble interleukin‐2 receptor levels in hairy cell leukaemia as a marker of tumour burden with prognostic value and as a tool for disease monitoring. British Journal of Haematology. https://doi.org/10.1111/bjh.70059
Vancouver
Angotzi F, Cellini A, Danesin N, Zoletto S, Serafin A, Cavarretta CA, et al. Serum soluble interleukin‐2 receptor levels in hairy cell leukaemia as a marker of tumour burden with prognostic value and as a tool for disease monitoring. British Journal of Haematology. 2025. doi:10.1111/bjh.70059
BibTeX
@article{Angotzi2025,
author = {Angotzi, Francesco and Cellini, Alessandro and Danesin, Nicolò and Zoletto, Simone and Serafin, Andrea and Cavarretta, Chiara Adele and Bevilacqua, Arianna and Forlani, Laura and Tonini, Alessia and Frezzato, Federica and Bonaldi, Laura and Pizzi, Marco and Faggian, Diego and Trentin, Livio and Visentin, Andrea},
title = {Serum soluble interleukin‐2 receptor levels in hairy cell leukaemia as a marker of tumour burden with prognostic value and as a tool for disease monitoring},
journal = {British Journal of Haematology},
year = {2025},
doi = {10.1111/bjh.70059}
}
EUVIMED